A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities

NCT07394374 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors Harboring NTRK Fusion
NTRK
NTRK Gene Fusion
NTRK Fusion Positive

Interventions

DRUG: CG001419 tablets

Sponsor

Cullgen (Shanghai),Inc